As political leaders from around the world get ready to meet at the COP 28 climate conference, life science companies are taking steps to encourage sustainability within industry.
Companies from across the global healthcare sector, including AstraZeneca (LSE: AZN), GSK (LSE: GSK), Novo Nordisk (NOV: N) and Roche (ROG: SIX), are working together on initiatives to reduce carbon emissions to zero.
The discussions are taking place under the aegis of the Sustainable Markets Initiative (SMI), a non-profit group launched in 2020 by the British King, Charles III, with a mission to “kickstart bold and imaginative action across the next decade.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze